FiDi-based obesity drug maker sees $1.9B IPO

Jan 31, 2025 · At the IPO price, the FiDi-based clinical-stage biotechnology company developing injectable and oral treatments for obesity and related conditions has a market value of about …

CouponFollow Extension

$1
OFF

FiDi-based Obesity Drug Maker Sees $1.9B IPO

2 weeks from now

Jan 31, 2025 · At the IPO price, the FiDi-based clinical-stage biotechnology company developing injectable and oral treatments for obesity and related conditions has a market value of about …

crainsnewyork.com

$415
OFF

Metsera, Maze Secure Combined $415 Million In IPOs

2 weeks from now

Jan 30, 2025 · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma …

biopharmadive.com

$1.18
OFF

Obesity-drug Maker Metsera Posts Largest Gain As IPOs Defy …

2 weeks from now

With 13.25 million Class A shares and 45.64 million Class B shares outstanding in the IPO, Infinity Natural Resources has a market capitalization of $1.18 billion based on the $20-a-share …

msn.com

47%
OFF

Obesity-drug Maker Metsera Posts Largest Gain As IPOs

2 weeks from now

Jan 31, 2025 · Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their …

marketwatch.com

$1
OFF

FiDi-based Obesity Drug Maker Sees $1.9B IPO

2 weeks from now

Jan 31, 2025 · Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

crainsnewyork.com

$275
OFF

Obesity Drug Developer Metsera Sets Terms For $275M IPO

2 weeks from now

Jan 27, 2025 · 2d illustrations and photos/iStock via Getty Images. Metsera (), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial …

seekingalpha.com

$640
OFF

Obesity Drug Developer BioAge Labs Aims Up To $640 Million …

2 weeks from now

Sep 25, 2024 · Richmond, California-based BioAge is seeking to raise as much as $199.5 million by offering 10.5 million shares at $17 to $19 each. It had earlier planned on offering 7.5 million …

usnews.com

$587
OFF

Obesity Drug Developer BioAge Seeks Up To $587 Mln Valuation In …

2 weeks from now

Sep 18, 2024 · Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according …

reuters.com

$410
OFF

Verdiva Launches With $410M And Weekly-dosed Oral GLP-1

2 weeks from now

Jan 9, 2025 · Verdiva launches with $410M series A to fund weekly-dosed weight loss drug trials, pipeline growth By James Waldron Jan 9, 2025 2:00am Verdiva Bio Obesity GLP-1 Amylin

fiercebiotech.com

$640
OFF

Obesity Drug Developer BioAge Labs Aims Up To $640 Million

2 weeks from now

Sep 25, 2024 · (Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a …

yahoo.com

$198
OFF

Obesity Drug Developer BioAge Raises $198m In IPO

2 weeks from now

Sep 26, 2024 · The expansion of the listing reflects the massive investor appetite for companies with assets in the clinic for obesity and takes the on-paper value of the Richmond, California …

pharmaphorum.com

$411
OFF

Verdiva Starts Up With $411M And A Portfolio Of Obesity Drugs …

2 weeks from now

Jan 9, 2025 · Dive Insight: Verdiva joins a long list of obesity drug startups launched over the last year, including Metsera, Antag Therapeutics, SixPeaks Bio, Pep2Tango Therapeutics and …

biopharmadive.com

$17
OFF

Obesity Drug Developer BioAge Sets IPO Terms (Pending:BIOA)

2 weeks from now

Sep 19, 2024 · Obesity drug developer BioAge Labs has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to …

seekingalpha.com

$587
OFF

Obesity Drug Developer BioAge Seeks Up To $587 Million ... - Yahoo

2 weeks from now

Sep 19, 2024 · Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, …

yahoo.com

41%
OFF

Obesity Drugs: Can New Firms Take Market Share From Eli

2 weeks from now

Sep 24, 2024 · US market penetration: We project 41% of diabetics and close to one fourth of nondiabetic obesity patients will be on a GLP-1 drug by 2031 based on the strong efficacy of …

morningstar.com

$200
OFF

A Weight Loss Drug Maker Is Aiming For A Big IPO - MSN

2 weeks from now

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently expanded, planned initial public offering, according to a filing with …

msn.com

$200
OFF

Weight Loss Drug Maker BioAge Labs Eyes $200 Million IPO - Quartz

2 weeks from now

Sep 25, 2024 · BioAge Labs wants to raise $200 million in IPO to develop obesity and diabetes drugs. ... California-based company said on Wednesday that it plans to offer 10.5 million …

qz.com

FAQs about FiDi-based obesity drug maker sees $1.9B IPO Coupon?

How much did Beta Bionics raise in its IPO?

Beta Bionics priced 12 million shares at the top of its increased estimated range of $16 to $17 a share, to raise $207 million in its IPO. The price level was a sign of strong demand for the IPO and an indicator of the gains seen once it started trading. ...

Is verdiva a new obesity drug startup?

Verdiva joins a long list of obesity drug startups launched over the last year, including Metsera, Antag Therapeutics, SixPeaks Bio, Pep2Tango Therapeutics and Kailera Therapeutics, which emerged from stealth just months ago with a $400 million financing. ...

Is the IPO market heating up for obesity-related startups?

Companies are also exploring multimodal approaches to address not only weight loss but also related complications such as diabetes and cardiovascular diseases. Lastly, the IPO market is heating up for obesity-related startups. ...

What is the future of the obesity drug market?

These gains reflect investors’ bullish outlook on the future of the obesity drug market. Morgan Stanley (MS) analysts anticipate the global market for GLP-1 drugs will reach $105 billion by 2030. BioAge is now trying to get in on the action. ...

How did Beta Bionics perform in 2024?

Beta Bionics reported a full-year 2024 net loss of $55.3 million on sales of $65.77 million, compared with a net loss of $44.1 million and revenue of $12 million for full-year 2023. Two biopharmaceutical companies also priced IPOs for trading on Friday. Maze Therapeutics Inc. priced 8.75 million shares at $16 a share for proceeds of $140 million. ...

How much did metsera IPO cost?

The stock traded at $16.12 a share recently and opened at $16 a share, flat with its IPO price. Metsera Inc. priced 15.28 million shares at $18 a share to raise $275 million. The stock opened at $25.50 and rose to $26.94 for a gain of about 50% over its IP price. ...